Ocular Therapeutix Inc (NAS:OCUL)
$ 11.0139 0.4139 (3.9%) Market Cap: 1.72 Bil Enterprise Value: 1.29 Bil PE Ratio: 0 PB Ratio: 4.53 GF Score: 66/100

Ocular Therapeutix Inc to Discuss Results From Its Phase 2 Clinical Trial of OTX-DED Call Transcript

Dec 06, 2021 / 01:00PM GMT
Release Date Price: $6.18 (+0.32%)
Operator

Good day, and thank you for standing by. Welcome to the Ocular Therapeutix conference call announcing top line results for Phase II clinical trial of OTX-DED for short-term treatment of dry eye disease. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions).

I would now like to hand the conference over to your speaker, Donald Notman, Chief Financial Officer. Please go ahead.

Donald Notman
Ocular Therapeutix, Inc. - CFO

Thank you, Shannon. Good morning, everyone, and thank you for joining us on our conference call announcing top line results for Phase II clinical trial of OTX-DED for the short-term treatment of dry eye disease. The press release and presentation can be accessed on the Investors portion of our website at investors.ocutx.com. Leading the call today will be Antony Mattessich, our President and Chief Executive Officer.

As a reminder, on today's call, certain statements we will be making may be considered forward-looking for the purposes of the Private Securities Litigation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot